Long

ObsEva, emerging company on verge of phase 3 completion


Hi Ya'll,
I hope you're having a Good Friday night. I came across this gem yesterday and I have to give it a shout out. ObsEva is a unique company, and has lots of potential. They have three drugs currently in pipelines. Its recently broken out and is channeling upward and moving very healthily. I have a price target of $10+. With a long term hold.

Yselty- Phase 3

Ebopripant - Phase 2

Nolasiban -Phase 1

obseva.com/our-pipeline-overview/


Yselty is about to be finished testing. It looks positive and ready to be sold world wide. This product is very good for dealing with uterary fibroids which is very common and has no clear medication to use to solve it.

If y'all can post your own understanding of the significance of these drugs I would appreciate it. I do not fully understand what these drugs do but they seem to be a big deal.

Many analysts have set price targets ranging from $4.00-$28.00 a share.
I will link this.

tipranks.com/stocks/obsv/forecast


Please give the company corporate presentation a look, and please tell me if I missed anything crucial, like the executives, etc..
obseva.com

Thanks,
Benjamin
Beyond Technical AnalysisbiotechBullish PatternsChart PatternsobsevaOBSVpharmaceuticalrunnerTrend Analysisvaginal

Also on:

Disclaimer